
## Arash O Naghavi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2818269/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. Brachytherapy, 2022, 21, 63-74.	0.5	3
2	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 140-149.	3.9	15
3	TMPRSS2â€ERG fusion impacts anterior tumor location in men with prostate cancer. Prostate, 2021, 81, 109-117.	2.3	4
4	PO43. Brachytherapy, 2021, 20, S76.	0.5	0
5	American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy. Brachytherapy, 2021, 20, 1200-1218.	0.5	4
6	Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization. Translational Oncology, 2021, 14, 101165.	3.7	24
7	Chemotherapy improves distant control in localized high-grade soft tissue sarcoma of the extremity/trunk. Clinical Sarcoma Research, 2020, 10, 11.	2.3	1
8	Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 356-361.	1.3	5
9	Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma. Clinical and Translational Radiation Oncology, 2020, 22, 22-28.	1.7	5
10	Sarcoma as a Model for Adolescent and Young Adult Care. Journal of Oncology Practice, 2019, 15, 239-247.	2.5	19
11	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Seminars in Radiation Oncology, 2019, 29, 111-125.	2.2	4
12	The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base. Cancer, 2019, 125, 642-651.	4.1	62
13	Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2019, 20, e1-e7.	2.6	14
14	Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 937-944.	1.3	4
15	Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial. Radiotherapy and Oncology, 2018, 127, 239-245.	0.6	5
16	The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. World Journal of Urology, 2018, 36, 1431-1440.	2.2	31
17	Quantitatively Excessive Normal Tissue Toxicity and Poor Target Coverage in Postoperative Lung Cancer Radiotherapy Meta-analysis. Clinical Lung Cancer, 2018, 19, e123-e130.	2.6	4
18	Extracranial metastatic burden in extensive-stage small cell lung cancer: implications for prophylactic cranial irradiation. Journal of Thoracic Disease, 2018, 10, 4321-4327.	1.4	3

ARASH O NAGHAVI

#	Article	IF	CITATIONS
19	The Future of Radiation Oncology in Soft Tissue Sarcoma. Cancer Control, 2018, 25, 107327481881550.	1.8	6
20	Patient choice for highâ€volume center radiation impacts head and neck cancer outcome. Cancer Medicine, 2018, 7, 4964-4979.	2.8	34
21	Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. Journal of Thoracic Oncology, 2018, 13, 1121-1127.	1.1	59
22	Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Management, 2018, 5, MMT02.	0.5	4
23	Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. Journal of Gastrointestinal Oncology, 2018, 9, 546-552.	1.4	3
24	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. Journal of Neuro-Oncology, 2017, 133, 331-338.	2.9	107
25	Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Therapeutic Advances in Hematology, 2017, 8, 129-138.	2.5	3
26	Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 473-482.	4.9	25
27	The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neuro-Oncology, 2017, 19, 1145-1146.	1.2	20
28	(PO41) Effect of HPV/P16 Status on Response to Postoperative Radiotherapy (RT) in Squamous Cell Carcinoma of the Penis (PECA). International Journal of Radiation Oncology Biology Physics, 2017, 98, E26.	0.8	0
29	Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy. JAMA Dermatology, 2017, 153, 1056.	4.1	13
30	Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy. Clinical Colorectal Cancer, 2017, 16, e211-e220.	2.3	33
31	Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. Journal of Geriatric Oncology, 2017, 8, 50-55.	1.0	23
32	Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma. Journal of Contemporary Brachytherapy, 2017, 1, 20-29.	0.9	5
33	Quality of Life after post-prostatectomy intensity modulated radiation therapy to the prostate bed with or without the use of gold fiducial markers for image guidance or higher total radiotherapy doses. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 628-637.	1.5	2
34	The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy. Journal of Contemporary Brachytherapy, 2016, 5, 386-390.	0.9	0
35	Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma. Brachytherapy, 2016, 15, 495-503.	0.5	10
36	The Impact of BMI on Dosimetric Quality in Low Dose Rate Prostate Brachytherapy. Brachytherapy, 2016, 15, S192-S193.	0.5	0

ARASH O NAGHAVI

#	Article	IF	CITATIONS
37	Treatment delays, race, and outcomes in head and neck cancer. Cancer Epidemiology, 2016, 45, 18-25.	1.9	74
38	Management of Oropharyngeal Cancer in the HPV Era. Cancer Control, 2016, 23, 197-207.	1.8	11
39	Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Annals of Surgical Oncology, 2016, 23, 3572-3578.	1.5	77
40	Determining optimal followâ€up in the management of human papillomavirusâ€positive oropharyngeal cancer. Cancer, 2016, 122, 634-641.	4.1	24
41	Viral hepatitis associated hepatocellular carcinoma outcomes with Y-90 radioembolization Journal of Clinical Oncology, 2016, 34, 414-414.	1.6	1
42	Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World Journal of Gastroenterology, 2016, 22, 10406.	3.3	18
43	Urinary and bowel quality of life after image-guided, intensity modulated radiation therapy to the prostate bed Journal of Clinical Oncology, 2016, 34, 312-312.	1.6	0
44	Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer. International Journal of Clinical Oncology, 2015, 20, 598-604.	2.2	15
45	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 631-638.	0.8	102
46	Proinflammatory Role for let-7 MicroRNAS in Experimental Asthma. Journal of Biological Chemistry, 2010, 285, 30139-30149.	3.4	222
47	Mouse let-7 miRNA populations exhibit RNA editing that is constrained in the 5'-seed/ cleavage/anchor regions and stabilize predicted mmu-let-7a:mRNA duplexes. Genome Research, 2008, 18, 1571-1581.	5.5	87
48	Novel MicroRNA Candidates and miRNA-mRNA Pairs in Embryonic Stem (ES) Cells. PLoS ONE, 2008, 3, e2548.	2.5	48